{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.501","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.3","upperLimit":"92.1","value":"88.7"},{"groupId":"OG001","lowerLimit":"81.5","upperLimit":"91.9","value":"86.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"DCR was the percentage of participants with a best overall response of CR, PR, or SD as per response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG000","title":"Abemaciclib + NSAI"},{"description":"Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG001","title":"Placebo + NSAI"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)","title":"Percentage of Participants With CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}